Prostate Cancer Clinical Trial
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
Summary
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
Eligibility Criteria
Inclusion Criteria:
The subject must have already received tremelimumab in another protocol
Females of childbearing potential must agree to practice a form of effective contraception for 12 months following any dose of study drug. The definition of effective contraception will be based on the judgement of the investigator.
Subject must be willing and able to provide written informed consent and to comply with scheduled visits and other trial procedures
Exclusion Criteria:
None
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Los Angeles California, 90024, United States
Tampa Florida, 33612, United States
Ann Arbor Michigan, 48109, United States
New York New York, 10016, United States
Houston Texas, 77030, United States
Newecastle Upon Tyne , NE7 7, United Kingdom
How clear is this clinincal trial information?